Monica Sneve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Monica Sneve has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Rolf Jorde
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway
8 shared publications Yngve Figenschau
5 shared publicationsGuri Grimnes
Tromsø Endocrine Research Group, Department of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway
4 shared publicationsNina Emaus
4 shared publicationsRolf Jorde
3 shared publications- Guri Grimnes
Division of Internal Medicine, University Hospital of North Norway, 9037 Tromsø, Norway
2 shared publications
Latest Publications
- Open Access
- 25 May 2023
- Published by Springer Nature in Research Square
Age-related Macular Degeneration – 8-year incidence and progression in a population living north of the Arctic Circle
Objectives: Estimate the 8-year incidence and progression of age-related macular degeneration in an elderly Caucasian population living north of the Arctic Circle. Methods: This population-based cohort study included 2806 participants from the Tromsø Eye Study. Participants ≥ 55 years at baseline examination in 2007-08, who were re-examined in 2015-16, and had gradable digital colour fundus photographs (CFP) from at least one eye at both time points were included. CFP was graded for the most severe phenotype based on drusen size, geographic atrophy (GA), and neovascular AMD (nvAMD). Participants were asked if they had received treatment for AMD. Positive answers were validated by medical records. We calculated incidence based on the grading of CFP alone and combined with information about treatment for nvAMD. Results: The overall incidence of late AMD (GA and nvAMD) was 2.0 per 1000 person-years, with an 8-year cumulative incidence of 1.6 %. Information about anti-VEGF therapy did not change this estimate. The incidence increased with age, reaching maximum of 8.1 per 1000 person-years for participants aged 75-79 years. Incident late AMD was strongly associated with drusen size at baseline; 32.2% of the participants aged 75-79 years with large drusen at baseline developed late AMD. The 8-year cumulative incidence for progression to a more severe AMD grade was 30.9 %. Conclusions: The incidence of late AMD in a population living north of the Arctic Circle is comparable to other populations with European ancestry. Older age and large drusen are associated with an increased risk of developing late AMD.
- 25 May 2023
- Published by Springer Nature in Research Square
Open AccessAge-related Macular Degeneration – 8-year incidence and progression in a population living north of the Arctic Circle
Objectives: Estimate the 8-year incidence and progression of age-related macular degeneration in an elderly Caucasian population living north of the Arctic Circle. Methods: This population-based cohort study included 2806 participants from the Tromsø Eye Study. Participants ≥ 55 years at baseline examination in 2007-08, who were re-examined in 2015-16, and had gradable digital colour fundus photographs (CFP) from at least one eye at both time points were included. CFP was graded for the most severe phenotype based on drusen size, geographic atrophy (GA), and neovascular AMD (nvAMD). Participants were asked if they had received treatment for AMD. Positive answers were validated by medical records. We calculated incidence based on the grading of CFP alone and combined with information about treatment for nvAMD. Results: The overall incidence of late AMD (GA and nvAMD) was 2.0 per 1000 person-years, with an 8-year cumulative incidence of 1.6 %. Information about anti-VEGF therapy did not change this estimate. The incidence increased with age, reaching maximum of 8.1 per 1000 person-years for participants aged 75-79 years. Incident late AMD was strongly associated with drusen size at baseline; 32.2% of the participants aged 75-79 years with large drusen at baseline developed late AMD. The 8-year cumulative incidence for progression to a more severe AMD grade was 30.9 %. Conclusions: The incidence of late AMD in a population living north of the Arctic Circle is comparable to other populations with European ancestry. Older age and large drusen are associated with an increased risk of developing late AMD.
- Open Access
- 14 March 2013
- Published by Hindawi Limited in ISRN Endocrinology
- Vol. 2013, 1-7
Supplementation with High Doses of Vitamin D to Subjects without Vitamin D Deficiency May Have Negative Effects: Pooled Data from Four Intervention Trials in Tromsø
Data were pooled from four randomized clinical trials with vitamin D performed in Tromsø with weight reduction, insulin sensitivity, bone density, and depression scores as endpoints. Serum lipids, glycated hemoglobin (), and high sensitivity C-Reactive Protein, (HS-CRP) were measured at baseline and after 6–12 months of supplementation with vitamin D 20 000 IU–40 000 IU per week versus placebo. A total of 928 subjects who completed the interventions were included. At baseline the mean serum 25-hydroxyvitamin D (25(OH)D) level in those given vitamin D was 55.9 (20.9) nmol/L and the mean increase was 82.4 (40.1) nmol/L. Compared with the placebo group there was in the vitamin D group at the end of the studies a slight, but significant, increase in of 0.04%, an increase in HS-CRP of 0.07 mg/L in those with serum 25(OH)D < 50 nmol/L, and in those with low baseline HDL-C and serum 25(OH)D < 50 nmol/L a slight decrease serum HDL-C of 0.08 mmol/L (). No serious side-effects were seen. In conclusion, in subjects without vitamin D deficiency, there is no improvement in serum lipids, , or HS-CRP with high dose vitamin D supplementation. If anything, the effect is negative.
- 14 March 2013
- Published by Hindawi Limited in ISRN Endocrinology
- Vol. 2013, 1-7
Open AccessSupplementation with High Doses of Vitamin D to Subjects without Vitamin D Deficiency May Have Negative Effects: Pooled Data from Four Intervention Trials in Tromsø
Data were pooled from four randomized clinical trials with vitamin D performed in Tromsø with weight reduction, insulin sensitivity, bone density, and depression scores as endpoints. Serum lipids, glycated hemoglobin (), and high sensitivity C-Reactive Protein, (HS-CRP) were measured at baseline and after 6–12 months of supplementation with vitamin D 20 000 IU–40 000 IU per week versus placebo. A total of 928 subjects who completed the interventions were included. At baseline the mean serum 25-hydroxyvitamin D (25(OH)D) level in those given vitamin D was 55.9 (20.9) nmol/L and the mean increase was 82.4 (40.1) nmol/L. Compared with the placebo group there was in the vitamin D group at the end of the studies a slight, but significant, increase in of 0.04%, an increase in HS-CRP of 0.07 mg/L in those with serum 25(OH)D < 50 nmol/L, and in those with low baseline HDL-C and serum 25(OH)D < 50 nmol/L a slight decrease serum HDL-C of 0.08 mmol/L (). No serious side-effects were seen. In conclusion, in subjects without vitamin D deficiency, there is no improvement in serum lipids, , or HS-CRP with high dose vitamin D supplementation. If anything, the effect is negative.
- Open Access
- 1 August 2010
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 163 (2) , 339-348
Effect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed
Objective: Because we found higher serum 25-hydroxyvitamin D (25(OH)D) levels among smokers than among non-smokers with analyses using an electrochemiluminescence immunoassay (ECLIA) from Roche, the purpose of the present study was to examine whether this difference between smokers and non-smokers was maintained using other serum 25(OH)D assays.Design: A cross-sectional population-based study on 6932 participants from the Tromsø study, 1994–1995, and one validation study comparing six different serum 25(OH)D assays in 53 non-smokers and 54 smokers were performed.Methods: The association between smoking, season and serum 25(OH)D as measured by ECLIA (Roche) was assessed in the population-based study using general linear models with multivariate adjustments. In the validation study, serum levels of 25(OH)D were analysed with liquid chromatography coupled with mass spectrometry assay from two different laboratories, RIA (DiaSorin), HPLC, RIA (IDS) and ECLIA (Roche). T-tests and linear mixed model analyses were performed to compare the serum 25(OH)D levels in smokers and non-smokers within and between the methods.Results: In the population-based study, the serum levels of 25(OH)D using the ECLIA method were 51.9, 53.2 and 72.0 nmol/l in never, former and current smokers (PP<0.01) using the ECLIA (Roche), while non-significantly lower serum levels of 25(OH)D were found in smokers using the other five methods.Conclusions: These two studies indicate that the ECLIA (Roche) overestimates serum 25(OH)D levels in smokers by unknown mechanisms. If confirmed, this might have clinical consequences, and the issue needs further exploration.
- 1 August 2010
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 163 (2) , 339-348
Open AccessEffect of smoking on the serum levels of 25-hydroxyvitamin D depends on the assay employed
Objective: Because we found higher serum 25-hydroxyvitamin D (25(OH)D) levels among smokers than among non-smokers with analyses using an electrochemiluminescence immunoassay (ECLIA) from Roche, the purpose of the present study was to examine whether this difference between smokers and non-smokers was maintained using other serum 25(OH)D assays.Design: A cross-sectional population-based study on 6932 participants from the Tromsø study, 1994–1995, and one validation study comparing six different serum 25(OH)D assays in 53 non-smokers and 54 smokers were performed.Methods: The association between smoking, season and serum 25(OH)D as measured by ECLIA (Roche) was assessed in the population-based study using general linear models with multivariate adjustments. In the validation study, serum levels of 25(OH)D were analysed with liquid chromatography coupled with mass spectrometry assay from two different laboratories, RIA (DiaSorin), HPLC, RIA (IDS) and ECLIA (Roche). T-tests and linear mixed model analyses were performed to compare the serum 25(OH)D levels in smokers and non-smokers within and between the methods.Results: In the population-based study, the serum levels of 25(OH)D using the ECLIA method were 51.9, 53.2 and 72.0 nmol/l in never, former and current smokers (PP<0.01) using the ECLIA (Roche), while non-significantly lower serum levels of 25(OH)D were found in smokers using the other five methods.Conclusions: These two studies indicate that the ECLIA (Roche) overestimates serum 25(OH)D levels in smokers by unknown mechanisms. If confirmed, this might have clinical consequences, and the issue needs further exploration.
- 31 May 2010
- Published by Elsevier in Thrombosis Research
- Vol. 125 (5) , e210-e213
Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D
- 31 May 2010
- Published by Elsevier in Thrombosis Research
- Vol. 125 (5) , e210-e213
Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D
- 6 April 2010
- Published by Wiley in Journal of Internal Medicine
- Vol. 267 (5) , 462-472
No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year
Abstract. Jorde R, Sneve M, Torjesen P, Figenschau Y (University of Tromsø, Tromsø; Medical Clinic University Hospital of North Norway, Tromsø; University Hospital of North Norway, Tromsø; Aker University Hospital, Oslo; University Hospital of North Norway, Tromsø; and University of Tromsø, Tromsø; Norway). No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010; 267:462–472.Background and Aim. Cross‐sectional studies indicate vitamin D to be of importance for glucose tolerance, blood pressure and serum lipids, but whether supplementation with vitamin D would improve cardio‐vascular risk factors is not known.Design and Setting. The study was a 1 year, double blind placebo‐controlled intervention trial performed at the University Hospital of North Norway from November 2005 to October 2007.Subjects. A total of 438 overweight or obese subjects, 21–70 years old, were included and 330 completed the study.Interventions. The subjects were randomized to vitamin D (cholecalciferol, vitamin D3) 40 000 IU per week (DD group), vitamin D 20 000 IU per week (DP group), or placebo (PP group). All subjects were given 500 mg calcium daily.Main Outcome Measures. Fasting serum lipids and blood pressure were measured and an oral glucose tolerance test performed at start and end of the study.Results. At baseline the mean serum 25(OH)D levels were 58 nmol L−1 (all subjects) and increased to 140 and 101 nmol L−1 in the DD and DP groups, respectively. No significant differences were found between the three groups regarding change in measures of glucose metabolism or serum lipids. In the DP group, there was a slight but significant increase in systolic blood pressure compared with the placebo group.Conclusions. Our results do not support a positive effect of vitamin D on glucose tolerance, blood pressure or serum lipids. Further studies in subjects with low serum 25(OH)D levels combined with impaired glucose tolerance, hypertension or dyslipidaemia are needed.
- 6 April 2010
- Published by Wiley in Journal of Internal Medicine
- Vol. 267 (5) , 462-472
No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year
Abstract. Jorde R, Sneve M, Torjesen P, Figenschau Y (University of Tromsø, Tromsø; Medical Clinic University Hospital of North Norway, Tromsø; University Hospital of North Norway, Tromsø; Aker University Hospital, Oslo; University Hospital of North Norway, Tromsø; and University of Tromsø, Tromsø; Norway). No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010; 267:462–472.Background and Aim. Cross‐sectional studies indicate vitamin D to be of importance for glucose tolerance, blood pressure and serum lipids, but whether supplementation with vitamin D would improve cardio‐vascular risk factors is not known.Design and Setting. The study was a 1 year, double blind placebo‐controlled intervention trial performed at the University Hospital of North Norway from November 2005 to October 2007.Subjects. A total of 438 overweight or obese subjects, 21–70 years old, were included and 330 completed the study.Interventions. The subjects were randomized to vitamin D (cholecalciferol, vitamin D3) 40 000 IU per week (DD group), vitamin D 20 000 IU per week (DP group), or placebo (PP group). All subjects were given 500 mg calcium daily.Main Outcome Measures. Fasting serum lipids and blood pressure were measured and an oral glucose tolerance test performed at start and end of the study.Results. At baseline the mean serum 25(OH)D levels were 58 nmol L−1 (all subjects) and increased to 140 and 101 nmol L−1 in the DD and DP groups, respectively. No significant differences were found between the three groups regarding change in measures of glucose metabolism or serum lipids. In the DP group, there was a slight but significant increase in systolic blood pressure compared with the placebo group.Conclusions. Our results do not support a positive effect of vitamin D on glucose tolerance, blood pressure or serum lipids. Further studies in subjects with low serum 25(OH)D levels combined with impaired glucose tolerance, hypertension or dyslipidaemia are needed.
- Open Access
- 10 March 2010
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 171 (8) , 903-908
Tracking of Serum 25-Hydroxyvitamin D Levels During 14 Years in a Population-based Study and During 12 Months in an Intervention Study
Low serum 25-hydroxyvitamin D (25(OH)D) levels are associated with risk factors for cardiovascular disease, and they also appear to predict later development of type 2 diabetes, cancer, and an increased mortality rate. These predictions are all based on a single 25(OH)D measurement, but so far there are no known reports on tracking of serum 25(OH)D levels. In the present Norwegian study, serum 25(OH)D levels were measured 1) in 2,668 subjects in the 1994 and 2008 Tromsø surveys and 2) every third month for 1 year in 94 subjects randomly assigned to placebo in a vitamin D intervention study. There was a marked seasonal variation in 25(OH)D, and, depending on the method of adjusting for season, the correlation coefficient between serum 25(OH)D measurements from 1994 and 2008 ranged from 0.42 to 0.52. In the 1-year intervention study, the correlation between baseline and 12-month values was 0.80. Apart from the effect of season, changes in weight, intake of vitamin D, and physical activity were related to change in serum 25(OH)D levels. Tracking of serum 25(OH)D appears similar to that for blood pressure and serum lipids, and it provides some support for the use of a single 25(OH)D measurement to predict future health outcomes.
- 10 March 2010
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 171 (8) , 903-908
Open AccessTracking of Serum 25-Hydroxyvitamin D Levels During 14 Years in a Population-based Study and During 12 Months in an Intervention Study
Low serum 25-hydroxyvitamin D (25(OH)D) levels are associated with risk factors for cardiovascular disease, and they also appear to predict later development of type 2 diabetes, cancer, and an increased mortality rate. These predictions are all based on a single 25(OH)D measurement, but so far there are no known reports on tracking of serum 25(OH)D levels. In the present Norwegian study, serum 25(OH)D levels were measured 1) in 2,668 subjects in the 1994 and 2008 Tromsø surveys and 2) every third month for 1 year in 94 subjects randomly assigned to placebo in a vitamin D intervention study. There was a marked seasonal variation in 25(OH)D, and, depending on the method of adjusting for season, the correlation coefficient between serum 25(OH)D measurements from 1994 and 2008 ranged from 0.42 to 0.52. In the 1-year intervention study, the correlation between baseline and 12-month values was 0.80. Apart from the effect of season, changes in weight, intake of vitamin D, and physical activity were related to change in serum 25(OH)D levels. Tracking of serum 25(OH)D appears similar to that for blood pressure and serum lipids, and it provides some support for the use of a single 25(OH)D measurement to predict future health outcomes.
- 4 March 2010
- Published by Springer Nature in European Journal of Nutrition
- Vol. 49 (7) , 401-407
Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromsø study
The serum 25-hydroxyvitamin D (25(OH)D) levels are lower in obese than lean subjects. The present study examines the cross-sectional and longitudinal relations between body mass index (BMI) and serum 25(OH)D, and the serum 25(OH)D response to vitamin D supplementation in relation to BMI. The Tromsø study is a longitudinal population-based multipurpose study. The fourth survey was conducted in 1994 and the sixth in 2008. The intervention study was a 1-year placebo-controlled randomized intervention trial, where the results from the 93 subjects given 40,000 IU per week are presented. A total of 10,229 subjects were included in the 2008 cross-sectional study. There was a significant negative association between serum 25(OH)D levels and BMI which was also present during the winter months. Serum 25(OH)D levels varied through seasons, but not BMI. In the longitudinal study from 1994 to 2008 which included 2,656 subjects, change in BMI was a significant negative predictor of change in 25(OH)D. In the intervention study, there was a significant and negative correlation between BMI and serum 25(OH)D both at baseline and at the end of the study. The increase in serum 25(OH)D after 1 year was significantly and inversely related to baseline BMI. We have confirmed the strong association between serum 25(OH)D and BMI. The very obese need higher vitamin D doses than lean subjects to achieve the same serum 25(OH)D levels.
- 4 March 2010
- Published by Springer Nature in European Journal of Nutrition
- Vol. 49 (7) , 401-407
Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromsø study
The serum 25-hydroxyvitamin D (25(OH)D) levels are lower in obese than lean subjects. The present study examines the cross-sectional and longitudinal relations between body mass index (BMI) and serum 25(OH)D, and the serum 25(OH)D response to vitamin D supplementation in relation to BMI. The Tromsø study is a longitudinal population-based multipurpose study. The fourth survey was conducted in 1994 and the sixth in 2008. The intervention study was a 1-year placebo-controlled randomized intervention trial, where the results from the 93 subjects given 40,000 IU per week are presented. A total of 10,229 subjects were included in the 2008 cross-sectional study. There was a significant negative association between serum 25(OH)D levels and BMI which was also present during the winter months. Serum 25(OH)D levels varied through seasons, but not BMI. In the longitudinal study from 1994 to 2008 which included 2,656 subjects, change in BMI was a significant negative predictor of change in 25(OH)D. In the intervention study, there was a significant and negative correlation between BMI and serum 25(OH)D both at baseline and at the end of the study. The increase in serum 25(OH)D after 1 year was significantly and inversely related to baseline BMI. We have confirmed the strong association between serum 25(OH)D and BMI. The very obese need higher vitamin D doses than lean subjects to achieve the same serum 25(OH)D levels.
- Open Access
- 7 January 2010
- Published by Springer Nature in Nutrition Journal
- Vol. 9 (1) , 1
No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year
In meta-analyses supplementation with vitamin D appears to reduce incidence of fractures, and in cross-sectional studies there is a positive association between serum 25-hydroxyvitamin D (25(OH)D) levels and bone mineral density (BMD). However, the effect of supplementation with high doses of vitamin D on BMD is more uncertain and could in theory have both positive and negative effects.
- 7 January 2010
- Published by Springer Nature in Nutrition Journal
- Vol. 9 (1) , 1
Open AccessNo significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year
In meta-analyses supplementation with vitamin D appears to reduce incidence of fractures, and in cross-sectional studies there is a positive association between serum 25-hydroxyvitamin D (25(OH)D) levels and bone mineral density (BMD). However, the effect of supplementation with high doses of vitamin D on BMD is more uncertain and could in theory have both positive and negative effects.